Figure 2
From: Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors
Pazopanib inhibits tumor growth in a xenograft orthotopic model of CDDP-primary refractory yolk sac testicular germ cell tumor. Mice with an orthotopically implanted TGT44 CDDP-refractory yolk sac tumor were treated with vehicle, four injections of 4 mg/kg CDDP or daily 100 mg/kg pazopanib for six weeks. Mice were sacrificed when control mouse tumors affected the wellbeing of the animals. Final volumes are illustrated by a boxplot. *, p < 0.05 (two-tail Mann–Whitney U test).